Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Penpulimab plus concurrent chemoradiotherapy for bladder preservation in muscle-invasive bladder cancer
ChiCTR2200060556Phase 2Not yet recruiting
- Sponsor
- Mianyang Central Hospital
- Start
- Apr 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of penpulimab in bladder cancer and muscle-invasive bladder cancer (MIBC), sponsored by Mianyang Central Hospital. Primary endpoint: Clinical complete remission rate. Planned start Apr 2022; status: not yet recruiting.
02
Drugs
penpulimab
03
Conditions
bladder cancermuscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on ChiCTR2200060556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200060556.